PSORAS
MCID: PSR001
MIFTS: 63

Psoriatic Arthritis (PSORAS)

Categories: Bone diseases, Genetic diseases, Immune diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Psoriatic Arthritis

MalaCards integrated aliases for Psoriatic Arthritis:

Name: Psoriatic Arthritis 57 11 42 75 73 41 14 16 75 33
Psoriatic Arthritis, Susceptibility to 57 28 12 5
Psoriatic Arthropathy 11 42 73 33
Arthropathic Psoriasis 11 42 31
Arthritis, Psoriatic 43 71
Arthritis, Psoriatic, Susceptibility to 38
Psoriasis Arthropathica 73
Arthritis Psoriatica 11
Arthritic Psoriasis 73
Arthritis Psoriatic 53
Psoras 73

Classifications:



External Ids:

Disease Ontology 11 DOID:9008
OMIM® 57 607507
ICD9CM 34 696.0
MeSH 43 D015535
NCIt 49 C61277
SNOMED-CT 68 33339001
ICD10 31 L40.5
UMLS 71 C0003872

Summaries for Psoriatic Arthritis

MedlinePlus Genetics: 42 Psoriatic arthritis is a condition involving joint inflammation (arthritis) that usually occurs in combination with a skin disorder called psoriasis. Psoriasis is a chronic inflammatory condition characterized by patches of red, irritated skin that are often covered by flaky white scales. People with psoriasis may also have changes in their fingernails and toenails, such as nails that become pitted or ridged, crumble, or separate from the nail beds.Signs and symptoms of psoriatic arthritis include stiff, painful joints with redness, heat, and swelling in the surrounding tissues. When the hands and feet are affected, swelling and redness may result in a "sausage-like" appearance of the fingers or toes (dactylitis).In most people with psoriatic arthritis, psoriasis appears before joint problems develop. Psoriasis typically begins during adolescence or young adulthood, and psoriatic arthritis usually occurs between the ages of 30 and 50. However, both conditions may occur at any age. In a small number of cases, psoriatic arthritis develops in the absence of noticeable skin changes.Psoriatic arthritis may be difficult to distinguish from other forms of arthritis, particularly when skin changes are minimal or absent. Nail changes and dactylitis are two features that are characteristic of psoriatic arthritis, although they do not occur in all cases.Psoriatic arthritis is categorized into five types: distal interphalangeal predominant, asymmetric oligoarticular, symmetric polyarthritis, spondylitis, and arthritis mutilans.The distal interphalangeal predominant type affects mainly the ends of the fingers and toes. The distal interphalangeal joints are those closest to the nails. Nail changes are especially frequent with this form of psoriatic arthritis.The asymmetric oligoarticular and symmetric polyarthritis types are the most common forms of psoriatic arthritis. The asymmetric oligoarticular type of psoriatic arthritis involves different joints on each side of the body, while the symmetric polyarthritis form affects the same joints on each side. Any joint in the body may be affected in these forms of the disorder, and symptoms range from mild to severe.Some individuals with psoriatic arthritis have joint involvement that primarily involves spondylitis, which is inflammation in the joints between the vertebrae in the spine. Symptoms of this form of the disorder involve pain and stiffness in the back or neck, and movement is often impaired. Joints in the arms, legs, hands, and feet may also be involved.The most severe and least common type of psoriatic arthritis is called arthritis mutilans. Fewer than 5 percent of individuals with psoriatic arthritis have this form of the disorder. Arthritis mutilans involves severe inflammation that damages the joints in the hands and feet, resulting in deformation and movement problems. Bone loss (osteolysis) at the joints may lead to shortening (telescoping) of the fingers and toes. Neck and back pain may also occur.

MalaCards based summary: Psoriatic Arthritis, also known as psoriatic arthritis, susceptibility to, is related to spondyloarthropathy 1 and juvenile rheumatoid arthritis, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Psoriatic Arthritis is LTA (Lymphotoxin Alpha), and among its related pathways/superpathways are Innate Immune System and PAK Pathway. The drugs Methotrexate and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and homeostasis/metabolism

MedlinePlus: 41 Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get them on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people with psoriasis have psoriatic arthritis. It causes pain, stiffness, and swelling of the joints. It is often mild, but can sometimes be serious and affect many joints. The joint and skin problems don't always happen at the same time. Your doctor will do a physical exam and imaging tests to diagnose psoriatic arthritis. There is no cure, but medicines can help control inflammation and pain. In rare cases, you might need surgery to repair or replace damaged joints.

UniProtKB/Swiss-Prot: 73 An inflammatory, seronegative arthritis associated with psoriasis. It is a heterogeneous disorder ranging from a mild, non-destructive disease to a severe, progressive, erosive arthropathy. Five types of psoriatic arthritis have been defined: asymmetrical oligoarthritis characterized by primary involvement of the small joints of the fingers or toes; asymmetrical arthritis which involves the joints of the extremities; symmetrical polyarthritis characterized by a rheumatoid like pattern that can involve hands, wrists, ankles, and feet; arthritis mutilans, which is a rare but deforming and destructive condition; arthritis of the sacroiliac joints and spine (psoriatic spondylitis).

OMIM®: 57 Psoriasis (177900) is a chronic inflammatory skin disease that may have an autoimmune basis. The disorder has a strong but complex genetic basis, with a concordance rate of 50 to 70% among monozygotic twins. Psoriatic arthritis affects more than 10% of patients with psoriasis and, in most cases, there is an association between the severity of the arthritis and the skin involvement (Gudjonsson et al., 2002). (607507) (Updated 08-Dec-2022)

Disease Ontology: 11 An arthritis that is characterized by joint inflammation that usually occurs in combination with psoriasis.

Wikipedia 75 Psoriatic arthritis: Arthritis is a term often used to mean any disorder that affects joints. Symptoms generally include... more...

Psoriatic arthritis: Psoriatic arthritis is a long-term inflammatory arthritis that occurs in people affected by the... more...

Related Diseases for Psoriatic Arthritis

Diseases related to Psoriatic Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 946)
# Related Disease Score Top Affiliating Genes
1 spondyloarthropathy 1 33.4 TNFSF11 TNFRSF1B TNF NOD2 MMP3 IL1B
2 juvenile rheumatoid arthritis 32.4 TNFRSF1B TNF PTPN22 LTA IL1B HLA-DRB1
3 psoriasis 32.4 TNFRSF1B TNF SELE S100A12 PTPN22 NOD2
4 arthritis 32.4 TNIP1 TNFSF11 TNFRSF1B TNF S100A12 PTPN22
5 spondylitis 32.2 TNFSF11 TNF NOD2 MICA LTA IL1B
6 arthropathy 32.1 TNFSF11 TNF NOD2 MMP3 MICA LTA
7 osteoarthritis 31.9 TNFSF11 TNF MMP3 IL1B CRP COMP
8 synovitis 31.9 TNFSF11 TNF SELE MMP3 IL1B CRP
9 enthesopathy 31.9 TNF HLA-B CRP
10 uveitis 31.8 TNF NOD2 LTA IL1B HLA-DRB1 HLA-B
11 skin disease 31.8 TNF SELE NOD2 MIR146A IL1B IL13
12 tenosynovitis 31.8 TNF NOD2 MMP3 IL1B CRP
13 reactive arthritis 31.7 TNF HLA-B CRP COMP
14 ankylosis 31.7 TNFSF11 TNF CRP
15 spondyloarthropathy 31.7 TNFSF11 TNF NOD2 IL1B HLA-DRB1 HLA-C
16 fibromyalgia 31.7 TNF IL1B CRP
17 gout 31.6 TNF IL1B HLA-B CRP
18 spondylarthropathy 31.5 TNF LTA CRP
19 exanthem 31.5 TNF IL1B HLA-B CRP
20 atherosclerosis susceptibility 31.5 TNF SELE IL1B CRP
21 periostitis 31.5 TNF IL1B CRP
22 bowel dysfunction 31.5 TNF NOD2 IL1B CRP
23 nasopharyngitis 31.5 TNF IL13 CRP
24 autoimmune disease 31.5 TNFRSF1B TNF PTPN22 MIR146A LTA IL1B
25 inflammatory bowel disease 1 31.5 TNF NOD2 IL1B
26 rheumatoid arthritis 31.4 TNIP1 TNFSF11 TNFRSF1B TNF SELE S100A12
27 lipid metabolism disorder 31.4 TNF SELE IL1B CRP
28 crohn's disease 31.4 TNF S100A12 NOD2 IL1B IL13 CRP
29 anterior uveitis 31.4 TNF IL1B HLA-DRB1 HLA-B CRP
30 bursitis 31.4 TNF IL1B CRP
31 back pain 31.4 MMP3 IL1B CRP
32 dermatitis 31.4 TNF NOD2 IL1B IL13
33 sapho syndrome 31.3 TNF NOD2 CRP
34 viral infectious disease 31.3 TNF IL1B IL13 HLA-B
35 systemic scleroderma 31.2 TNF IL1B IL13 HLA-DRB1 CRP
36 cartilage disease 31.2 TNF MMP3 IL1B CRP COMP
37 diarrhea 31.2 TNF NOD2 IL1B IL13
38 ulcerative colitis 31.2 TNF S100A12 NOD2 IL1B IL13 HLA-DRB1
39 vasculitis 31.2 TNFRSF1B TNF SELE IL1B HLA-DRB1 HLA-B
40 covid-19 31.1 TNF IL1B HLA-C CRP
41 thyroiditis 31.1 TNF PTPN22 IL1B HLA-DRB1 CRP
42 pyoderma 31.1 TNF NOD2 IL1B CRP
43 leishmaniasis 31.1 TNF LTA IL1B IL13
44 chickenpox 31.1 TNF IL1B CRP
45 vascular disease 31.1 TNF SELE MMP3 MIR146A CRP
46 sleep disorder 31.1 TNF IL1B CRP
47 pyoderma gangrenosum 31.1 TNF NOD2 IL1B
48 severe acute respiratory syndrome 31.0 TNF IL1B HLA-C CRP
49 bone inflammation disease 31.0 TNFSF11 TNF PTPN22 MMP3 MIR146A IL1B
50 periodontitis 31.0 TNFSF11 TNF MMP3 IL1B CRP

Graphical network of the top 20 diseases related to Psoriatic Arthritis:



Diseases related to Psoriatic Arthritis

Symptoms & Phenotypes for Psoriatic Arthritis

Clinical features from OMIM®:

607507 (Updated 08-Dec-2022)

UMLS symptoms related to Psoriatic Arthritis:


back pain; sciatica; muscle cramp

GenomeRNAi Phenotypes related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

25 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.68 MICA
2 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.68 HLA-B HLA-C
3 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.68 MICA
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.68 HLA-C
5 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.68 MICA
6 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.68 HLA-C
7 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.68 SELE
8 Increased shRNA abundance (Z-score > 2) GR00366-A-162 9.68 HLA-C
9 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.68 SELE
10 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.68 SELE
11 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.68 NOD2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-26 9.68 SELE
13 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.68 NOD2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-38 9.68 SELE
15 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.68 SELE
16 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.68 MICA
17 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.68 HLA-C
18 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.68 MICA
19 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.68 HLA-B HLA-C
20 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.68 MICA
21 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.68 HLA-C

MGI Mouse Phenotypes related to Psoriatic Arthritis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.28 COMP CRP IL13 IL1B LTA MIR146A
2 growth/size/body region MP:0005378 10.25 COMP HLA-B HLA-C HLA-DRB1 IL13 IL1B
3 endocrine/exocrine gland MP:0005379 10.07 HLA-B HLA-C IL13 LTA NOD2 PTPN22
4 immune system MP:0005387 10.06 COMP CRP HLA-B HLA-C IL13 IL1B
5 no phenotypic analysis MP:0003012 10 HLA-B HLA-C IL13 MIR146A TNF TNFSF11
6 cardiovascular system MP:0005385 10 COMP CRP HLA-B HLA-C IL1B LTA
7 digestive/alimentary MP:0005381 9.92 HLA-B HLA-C IL13 NOD2 PTPN22 TNF
8 skeleton MP:0005390 9.7 COMP HLA-DRB1 IL13 IL1B LTA MIR146A
9 hematopoietic system MP:0005397 9.47 HLA-B HLA-C IL13 IL1B LTA MIR146A

Drugs & Therapeutics for Psoriatic Arthritis

Drugs for Psoriatic Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
2
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
3
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
5
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
7
Golimumab Approved Phase 4 476181-74-5
8
Adalimumab Approved, Experimental Phase 4 331731-18-1
9
Upadacitinib Approved, Investigational Phase 4 1310726-60-3 76829165 58557659
10
Tofacitinib Approved, Investigational Phase 4 477600-75-2 9926791
11
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
12
Etanercept Approved, Investigational Phase 4 185243-69-0
13
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
14
Sulfasalazine Approved Phase 4 599-79-1 5353980 5339 5359476
15
Certolizumab pegol Approved Phase 4 428863-50-7
16
Ixekizumab Approved, Investigational Phase 4 1143503-69-8
17
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
18
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
19
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
20 Hormones Phase 4
21 Hormone Antagonists Phase 4
22 Immunosuppressive Agents Phase 4
23 Melanocyte-Stimulating Hormones Phase 4
24 Adrenocorticotropic Hormone Phase 4
25
beta-Endorphin Phase 4
26 Antineoplastic Agents, Hormonal Phase 4
27 Neuroprotective Agents Phase 4
28 Antiemetics Phase 4
29 glucocorticoids Phase 4
30
Methylprednisolone Acetate Phase 4 584547
31 Protective Agents Phase 4
32 Methylene diphosphonate Phase 4
33 Diphosphonates Phase 4
34 Immunologic Factors Phase 4
35 Dermatologic Agents Phase 4
36 Protein Kinase Inhibitors Phase 4
37 Tumor Necrosis Factor Inhibitors Phase 4
38 Janus Kinase Inhibitors Phase 4
39 Folic Acid Antagonists Phase 4
40 Folate Phase 4
41 Vitamin B9 Phase 4
42 Vitamin B Complex Phase 4
43 Immune Checkpoint Inhibitors Phase 4
44 Gastrointestinal Agents Phase 4
45 Vaccines Phase 4
46 Anti-Bacterial Agents Phase 4
47 Angiogenesis Inhibitors Phase 4
48
Lactitol Approved, Investigational Phase 3 585-86-4 157355
49
Ustekinumab Approved, Investigational Phase 3 815610-63-0
50
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337

Interventional clinical trials:

(show top 50) (show all 446)
# Name Status NCT ID Phase Drugs
1 Title of Study: A Single-Site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection) an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Psoriatic Arthritis (PsA) Unknown status NCT01939132 Phase 4 Open label H.P. Acthar Gel
2 Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarkers - ABEPSA _ BB Unknown status NCT04106804 Phase 4 Abatacept 125 MG/ML
3 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
4 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
5 Prevalence, Pattern and Disease Course og Arthritis and Enthesitis in Patients With Psoriasis, and Effect of Apremilast in Subclinical, US-defined Psoriatic Arthritis - a Population Based Study Applying Clinical, Ultrasonic, MRI and Patient-reported Outcomes Unknown status NCT04515732 Phase 4 Apremilast Oral Tablet
6 A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis Completed NCT03733925 Phase 4 Golimumab
7 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis After 16 Weeks of Treatment Compared to Placebo and to Assess the Safety, Tolerability and Efficacy up to 52 Weeks Completed NCT02798211 Phase 4 Secukinumab 300 mg;Secukinumab 150 mg
8 A Phase 4, Multicenter, Single-Arm, Open-Label Study to Evaluate the Impact of Apremilast (CC-10004) Monotherapy on MRI Outcomes in Subjects With Active Psoriatic Arthritis Completed NCT03783026 Phase 4 CC-10004
9 TNF-α Blockade for Psoriatic Arthritis - A Clinical and MRI Study, and the Effects on Cytokine and Cardiovascular Risk Profile Completed NCT00432406 Phase 4 Infliximab;Etanercept
10 An Extension Study of Brodalumab in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma Completed NCT04183881 Phase 4 Brodalumab 210mg SC
11 A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
12 Rating Evaluations in Psoriatic Arthritis (PsA) With Enbrel® Completed NCT00127842 Phase 4 Etanercept
13 A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive Completed NCT03151551 Phase 4 Ixekizumab;Adalimumab
14 Enbrel® in Psoriatic Arthritis Completed NCT00111124 Phase 4 Enbrel®
15 A RANDOMIZED, OPEN-LABEL, TWO-PERIOD STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ETANERCEPT ON SKIN AND JOINT DISEASE IN PSORIASIS SUBJECTS WITH PSORIATIC ARTHRITIS Completed NCT00245960 Phase 4 etanercept;Placebo
16 Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS) Completed NCT03419650 Phase 4 ACTHar
17 Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice Completed NCT01147874 Phase 4
18 A Phase 4 Open-label Randomized Controlled Study COmparing the Effectiveness of Adalimumab iNTROduction and Methotrexate Dose escaLation in Subjects With Psoriatic Arthritis (CONTROL) Completed NCT02814175 Phase 4 methotrexate (MTX)
19 A Pilot Study of Technetium [99Tc] Methylene Diphosphonate in the Treatment of Psoriatic Arthritis Completed NCT05000086 Phase 4 99Tc methylene diphosphonate
20 Can New Imaging- and Biomarkers Improve the Assessment of Disease Activity and Progression and Predict Therapeutic Outcome in Psoriatic Arthritis Patients Receiving Adalimumab? Completed NCT01465438 Phase 4 Adalimumab
21 Microarray Analysis of Peripheral Blood and Tissues of Patients With Immune Mediated Inflammatory Diseases Completed NCT00462072 Phase 4 Infliximab
22 Clinical Effectiveness of Symptomatic Therapy Compared to Standard Step up Care for the Treatment of Low Impact Psoriatic Oligoarthritis: a 2 Arm Parallel Group Feasibility Study Completed NCT03797872 Phase 4 Methotrexate;Sulfasalazine;Leflunomide;Methylprednisolone;Triamcinolone
23 TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
24 A Multicenter, Open-label, Randomized, Pilot-study to Evaluate the Efficacy and Safety of the Combination of Etanercept (ETN) and Methotrexate and of Etanercept (ETN) Alone in Patients With Plaque Psoriasis Despite Methotrexate Therapy Completed NCT00161655 Phase 4 Etanercept;Methotrexate
25 Clinical Effectiveness of Standard Step up Care (Methotrexate) Compared to Early Combination DMARD Therapy With Standard Step up Care Compared to Early Use of TNF Inhibitors With Standard Step up Care for the Treatment of Moderate to Severe Psoriatic Arthritis: a 3-arm Parallel Group Randomised Controlled Trial. Recruiting NCT03739853 Phase 4 Methotrexate;Sulfasalazine;Leflunomide;Adalimumab
26 A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease Recruiting NCT04929210 Phase 4 Guselkumab;Placebo
27 Prevention of Metacarpophalangeal Joints Structure Damage in Patients With Psoriatic Arthritis Using Secukinumab Recruiting NCT03623867 Phase 4 Secukinumab;Placebo
28 Monitoring Nail Changes in Patients With Psoriatic Disease Treated With Etanercept Using Non- Invasive Optical Coherence Tomography Recruiting NCT05135312 Phase 4 Etanercept
29 The SARS-CoV-2 Vaccine Response and Safety in Rheumatology Patients and the Influence of Temporary Interruptions in Immunomodulatory Therapy Recruiting NCT05080218 Phase 4 Upadacitinib;Abatacept;Secukinumab;Tofacitinib;TNF Inhibitor;Canakinumab Injection;Baricitinib;Ixekizumab
30 A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Early, Oligoarticular Psoriatic Arthritis Despite Initial Stable Treatment With Either NSAIDS and/or ≤ 1 Conventional Synthetic DMARD Active, not recruiting NCT03747939 Phase 4 Apremilast (CC-10004)
31 EBIO - Enthesitis Biopsy Study Active, not recruiting NCT04887597 Phase 4 Secukinumab
32 Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis Who Have an Inadequate Skin Response to Anti-IL23 Therapy Not yet recruiting NCT05499416 Phase 4 Bimekizumab
33 Validation of the PsASon ULtrasound Scores in Patients With Psoriatic Arthritis Undergoing TReatment With Apremilast Withdrawn NCT04102449 Phase 4 Apremilast
34 A Skin and Synovial Tissue Assessment of Overlapping Genes and Their Response After 3 Months Treatment With Apremilast in Patients With Psoriatic Arthritis Withdrawn NCT02558361 Phase 4 Treatment with Apremilast
35 SystemIc iNflammation and Microvascular diSease PreventIon in psoRiatic diseasE Withdrawn NCT04417114 Phase 4 Rosuvastatin
36 Assessment of the Clinical and Ultrasound Response to Apremilast by Clinical Evaluation and by a Joint-periarticular-nail Ultrasound Index in Patients With Active Psoriatic Arthritis Unknown status NCT03191539 Phase 3 Apremilast
37 An Investigator-initiated Double-blind, Parallel-group Randomised Controlled Trial of GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA Using Clinical and Whole Body MRI Outcomes: the GOLMePsA Study. Unknown status NCT04108468 Phase 3 Golimumab;Methotrexate
38 MAXIMISE (Managing AXIal Manifestations in PsorIatic Arthritis With SEcukinumab), a Randomized, Double-blind, Placebo-controlled, Multicenter, 52-week Study to Assess the Efficacy and Safety of Secukinumab 150 mg or 300 mg s.c. in Participants With Active Psoriatic Arthritis and Axial Skeleton Involvement Who Have Inadequate Response to Non-steroidal Anti-inflammatory Drugs (NSAIDs) Completed NCT02721966 Phase 3 Secukinumab and Placebo
39 A Multicenter, Randomized, Open-Label Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or Auto-Injector for the Subcutaneous Self-Injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis Completed NCT04109976 Phase 3 Bimekizumab
40 A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Psoriatic Arthritis Completed NCT01989468 Phase 3
41 A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor Completed NCT01882439 Phase 3 Tofacitinib
42 A Randomized, Double-blind, Placebo-controlled Trial of Golimumab+Methotrexate Versus Methotrexate Alone in Methotrexate-naïve Patients With Psoriatic Arthritis Completed NCT01871649 Phase 3 golimumab;methotrexate
43 A 52-week, Multicenter Study to Assess the Time Course of Response to Secukinumab on Joint Inflammation Using Power Doppler Ultrasonography in Patients With Active Psoriatic Arthritis Completed NCT02662985 Phase 3 AIN457 (secukinumab);Placebo
44 An Extension Study of KHK4827 in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma Completed NCT02052609 Phase 3 KHK4827 140mg SC;KHK4827 210mg SC
45 A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab, to Demonstrate Efficacy After Twelve Weeks of Treatment and to Assess Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis With or Without Psoriatic Arthritis Comorbidity Completed NCT03066609 Phase 3 Secukinumab 150 mg s.c.;Secukinumab 300 mg s.c.;Placebo
46 A Single-arm, Multicenter Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Electromechanical Autoinjector to Self-inject Etanercept Completed NCT01901185 Phase 3 Etanercept / Autoinjector A
47 Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy Completed NCT00646178 Phase 3 adalimumab;placebo for adalimumab
48 A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Psoriatic Arthritis Completed NCT04209205 Phase 3 Secukinumab;Placebo
49 Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis Completed NCT03736161 Phase 3 Group A- Tofacitinib;Group B- Methotrexate
50 A Multicenter, Randomized, Double-blind, Crossover Study to Assess the Injection Site Pain Associated With a Modified Etanercept Formulation in Adult Subjects With Either Rheumatoid Arthritis or Psoriatic Arthritis Completed NCT02986139 Phase 3 Commercial Formulation Etanercept;New Formulation Etanercept

Search NIH Clinical Center for Psoriatic Arthritis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Auranofin
Aurothioglucose
Etanercept

Cochrane evidence based reviews: arthritis, psoriatic

Genetic Tests for Psoriatic Arthritis

Genetic tests related to Psoriatic Arthritis:

# Genetic test Affiliating Genes
1 Psoriatic Arthritis, Susceptibility to 28 LTA

Anatomical Context for Psoriatic Arthritis

Organs/tissues related to Psoriatic Arthritis:

MalaCards : Skin, Bone, T Cells, Endothelial, Liver, Breast, Bone Marrow

Publications for Psoriatic Arthritis

Articles related to Psoriatic Arthritis:

(show top 50) (show all 11334)
# Title Authors PMID Year
1
Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. 62 57 5
12746914 2003
2
CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. 53 62 57
12879366 2003
3
Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. 53 62 57
12639988 2003
4
Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. 62 57
18800148 2009
5
PSORS2 markers are not associated with psoriatic arthritis in the Italian population. 62 57
16733365 2006
6
A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting. 62 57
12474146 2003
7
HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features. 62 57
11841557 2002
8
HLA-C locus alleles in patients with psoriatic arthritis (PsA). 62 57
10321964 1999
9
The causal relationship between psoriasis, psoriatic arthritis, and inflammatory bowel diseases. 62 41
36443384 2022
10
Four emerging immune cellular blood phenotypes associated with disease duration and activity established in Psoriatic Arthritis. 62 41
36447253 2022
11
Regulatory T cells in psoriatic arthritis: an IL-17A-producing, Foxp3intCD161 + RORγt + ICOS + phenotype, that associates with the presence of ADAMTSL5 autoantibodies. 62 41
36450783 2022
12
The role of microRNA-146a (miR-146a) and its target IL-1R-associated kinase (IRAK1) in psoriatic arthritis susceptibility. 62 46
20500689 2010
13
Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility. 5
16418737 2006
14
An association between asthma and TNF-308G/A polymorphism: meta-analysis. 5
16865291 2006
15
Association of tumor necrosis factor polymorphisms with asthma and serum total IgE. 5
14681301 2004
16
Association between the tumor necrosis factor-alpha -308 G/A gene polymorphism and migraine. 5
14718719 2004
17
Association between G-308A polymorphism of the tumor necrosis factor-alpha gene and 24-hour ambulatory blood pressure values in type 1 diabetic adolescents. 5
12485196 2002
18
Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. 5
12426569 2002
19
Relation between tumour necrosis factor polymorphism TNFalpha-308 and risk of asthma. 5
11896460 2002
20
Association of polymorphisms and allelic combinations in the tumour necrosis factor-alpha-complement MHC region with coronary artery disease. 5
11826025 2002
21
Increased frequency of the tumor necrosis factor-alpha-308 A allele in adults with human immunodeficiency virus dementia. 5
11506397 2001
22
Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. 5
11261930 2001
23
Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. 5
10450718 1999
24
Genetic contribution of the tumor necrosis factor region in Guillain-Barré syndrome. 5
9818939 1998
25
Significantly earlier age at onset for the HLA-Cw6-positive than for the Cw6-negative psoriatic sibling. 57
9347803 1997
26
Comparative analysis of the genetic associations of HLA-DR3 and tumour necrosis factor alpha with human IDDM. 5
8056188 1994
27
Lipoma arborescens co-existing with psoriatic arthritis releases tumour necrosis factor alpha and matrix metalloproteinase 3. 53 62
20237127 2010
28
Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide association. 53 62
20415816 2010
29
The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project. 53 62
19904485 2010
30
Infliximab and anterior optic neuropathy: case report and review of the literature. 53 62
19916016 2010
31
Possible association between NOD2 variants and joint surgery in psoriatic arthritis. 53 62
20346235 2010
32
A case of tuberculous arthritis following the use of etanercept. 53 62
19949742 2009
33
Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking. 53 62
19554022 2009
34
Psoriatic arthritis: pharmacoeconomic considerations. 53 62
19691929 2009
35
Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? 53 62
19479708 2009
36
Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. 53 62
19188093 2009
37
Spondyloarthropathies: Targeted therapy for psoriatic arthritis. 53 62
19412187 2009
38
Follow-up of psoriatic arthritis mutilans patients treated with anti-TNF-alpha therapy. 53 62
19363860 2009
39
Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity. 53 62
19505409 2009
40
Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another? 53 62
19151120 2009
41
Leukemic phase of follicular lymphoma after treatment with etanercept in a patient with psoriasis. 53 62
19222252 2009
42
Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. 53 62
19016693 2009
43
Generalized pustulosis induced by adalimumab in a patient with rheumatoid arthritis - a therapeutic challenge. 53 62
18986481 2008
44
Etanercept in therapy multiresistant overlapping pityriasis lichenoides. 53 62
19112768 2008
45
Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data. 53 62
19036225 2008
46
Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis. 53 62
18694376 2008
47
Spinal epidural abscess associated with infliximab treatment for psoriatic arthritis. Case report. 53 62
18928222 2008
48
Genome-wide association scan in psoriasis: new insights into chronic inflammatory disease. 53 62
20476959 2008
49
Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. 53 62
18503600 2008
50
[First manifestation of psoriasis vulgaris in tumor necrosis factor receptor-associated periodic syndrome during treatment with etanercept]. 53 62
18210001 2008

Variations for Psoriatic Arthritis

ClinVar genetic disease variations for Psoriatic Arthritis:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 LTA, LOC100287329 NM_000595.4(LTA):c.-10+90A>G SNV Risk Factor
14380 rs909253 GRCh37: 6:31540313-31540313
GRCh38: 6:31572536-31572536
2 TNF NM_000594.3(TNF):c.-488G>A SNV Risk Factor
225964 rs1800629 GRCh37: 6:31543031-31543031
GRCh38: 6:31575254-31575254
3 NOD2 NM_001370466.1(NOD2):c.2641G>C (p.Gly881Arg) SNV Uncertain Significance
4692 rs2066845 GRCh37: 16:50756540-50756540
GRCh38: 16:50722629-50722629
4 NOD2 NM_001370466.1(NOD2):c.2183C>T (p.Ala728Val) SNV Uncertain Significance
319462 rs61747625 GRCh37: 16:50746086-50746086
GRCh38: 16:50712175-50712175
5 NOD2 NM_001370466.1(NOD2):c.2631G>A (p.Leu877=) SNV Uncertain Significance
319472 rs142559533 GRCh37: 16:50753917-50753917
GRCh38: 16:50720006-50720006
6 NOD2 NM_001370466.1(NOD2):c.1970G>A (p.Arg657Gln) SNV Uncertain Significance
779017 rs114664276 GRCh37: 16:50745873-50745873
GRCh38: 16:50711962-50711962
7 NOD2 NM_001370466.1(NOD2):c.2116G>A (p.Val706Met) SNV Uncertain Significance
992540 rs746055479 GRCh37: 16:50746019-50746019
GRCh38: 16:50712108-50712108
8 NOD2 NM_001370466.1(NOD2):c.963A>G (p.Leu321=) SNV Uncertain Significance
1675106 GRCh37: 16:50744866-50744866
GRCh38: 16:50710955-50710955
9 NOD2 NM_001370466.1(NOD2):c.1753G>A (p.Ala585Thr) SNV Uncertain Significance
4700 rs104895438 GRCh37: 16:50745656-50745656
GRCh38: 16:50711745-50711745
10 NOD2 NM_001370466.1(NOD2):c.2782G>A (p.Val928Ile) SNV Likely Benign
97869 rs5743291 GRCh37: 16:50757276-50757276
GRCh38: 16:50723365-50723365

Expression for Psoriatic Arthritis

Search GEO for disease gene expression data for Psoriatic Arthritis.

Pathways for Psoriatic Arthritis

Pathways related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.58 CRP HLA-B HLA-C HLA-DRB1 IL13 IL1B
2
Show member pathways
13.2 TNFSF11 TNFRSF1B TNF PTPN22 LTA IL1B
3
Show member pathways
12.81 TNFSF11 TNFRSF1B TNF S100A12 NOD2 MMP3
4
Show member pathways
12.53 TNF LTA IL1B IL13 HLA-C HLA-B
5
Show member pathways
12.53 TNIP1 TNFSF11 TNFRSF1B TNF LTA IL1B
6 12.4 TNIP1 TNFSF11 TNFRSF1B TNF PTPN22 IL1B
7
Show member pathways
12.38 S100A12 NOD2 IL1B IL13
8 11.91 TNFRSF1B TNF LTA IL1B IL13
9 11.75 TNFRSF1B TNF MMP3 IL1B IL13
10
Show member pathways
11.7 IL1B LTA TNF TNFRSF1B
11 11.68 IL13 IL1B LTA TNF
12
Show member pathways
11.65 TNFSF11 TNFRSF1B TNF
13 11.58 TNF IL1B IL13
14
Show member pathways
11.56 TNF SELE MMP3 IL1B
15
Show member pathways
11.55 TNF NOD2 IL13
16 11.53 TNFSF11 TNF LTA IL1B
17 11.49 TNFRSF1B TNF LTA
18 11.42 IL1B TNF TNFRSF1B
19 11.4 TNFSF11 TNF IL1B
20 11.31 HLA-DRB1 HLA-C HLA-B
21 11.22 TNF IL1B IL13
22 11.18 TNF MMP3 IL1B
23 11.14 TNF MICA IL1B IL13 HLA-DRB1 HLA-C
24 11.02 TNF IL1B IL13 HLA-DRB1
25 10.92 TNFSF11 TNF LTA IL1B IL13
26 10.7 IL1B IL13

GO Terms for Psoriatic Arthritis

Cellular components related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 TNFSF11 TNF SELE S100A12 MMP3 MIR146A
2 obsolete integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.13 HLA-DRB1 HLA-C HLA-B

Biological processes related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.36 CRP IL13 IL1B MIR146A PTPN22 TNF
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.22 TNFSF11 TNF S100A12 NOD2 IL1B
3 positive regulation of inflammatory response GO:0050729 10.21 TNIP1 TNF S100A12 IL1B
4 positive regulation of JNK cascade GO:0046330 10.19 TNFSF11 TNF NOD2 IL1B
5 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.18 TNFSF11 TNF S100A12 NOD2 IL1B HLA-DRB1
6 defense response GO:0006952 10.17 HLA-B NOD2 TNF TNIP1
7 positive regulation of type II interferon production GO:0032729 10.16 TNF PTPN22 LTA IL1B
8 positive regulation of phagocytosis GO:0050766 10.13 TNF NOD2 IL1B
9 immune system process GO:0002376 10.11 S100A12 PTPN22 NOD2 HLA-DRB1 HLA-C HLA-B
10 lipopolysaccharide-mediated signaling pathway GO:0031663 10.11 TNF PTPN22 IL1B
11 I-kappaB kinase/NF-kappaB signaling GO:0007249 10.1 TNFSF11 TNF NOD2 IL1B
12 defense response to Gram-positive bacterium GO:0050830 10.09 CRP IL1B LTA NOD2 TNF
13 regulation of inflammatory response GO:0050727 10.08 TNIP1 TNF SELE NOD2
14 JNK cascade GO:0007254 10.08 TNFSF11 TNF NOD2 IL1B
15 cellular response to lipopolysaccharide GO:0071222 10.07 TNIP1 TNFRSF1B TNF NOD2 MIR146A IL1B
16 inflammatory response GO:0006954 10.06 TNIP1 TNFRSF1B TNF SELE S100A12 IL1B
17 positive regulation of glial cell proliferation GO:0060252 10.01 TNF LTA IL1B
18 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.99 IL1B TNF TNFRSF1B
19 positive regulation of MAP kinase activity GO:0043406 9.96 TNFSF11 TNF S100A12 NOD2 IL1B
20 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.95 HLA-C HLA-B
21 positive regulation of fever generation GO:0031622 9.94 TNF IL1B
22 detection of bacterium GO:0016045 9.93 NOD2 HLA-DRB1 HLA-B
23 sequestering of triglyceride GO:0030730 9.92 TNF IL1B
24 immune response GO:0006955 9.89 HLA-B HLA-C HLA-DRB1 IL13 IL1B LTA
25 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.88 TNF IL1B
26 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.87 TNF LTA
27 cell communication GO:0007154 9.83 TNFSF11 TNF LTA
28 antigen processing and presentation GO:0019882 9.8 HLA-DRB1 HLA-C HLA-B
29 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.8 LTA NOD2 TNF
30 leukocyte migration GO:0050900 9.77 IL1B SELE TNF
31 signaling GO:0023052 9.75 TNFSF11 TNF LTA
32 response to lipopolysaccharide GO:0032496 9.44 TNFRSF1B TNF SELE PTPN22 NOD2 LTA

Molecular functions related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.73 HLA-DRB1 HLA-C HLA-B
2 cytokine activity GO:0005125 9.65 TNFSF11 TNF LTA IL1B IL13
3 tumor necrosis factor receptor binding GO:0005164 9.63 TNFSF11 TNF LTA
4 TAP binding GO:0046977 8.92 HLA-C HLA-B

Sources for Psoriatic Arthritis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....